Shifting towards a model of mGluR5 dysregulation in schizophrenia: Consequences for future schizophrenia treatment

Journal article


Matosin, Natalie, Fernandez-Enright, Francesca, Lum, Jeremy S. and Newell, Kelly A.. (2017). Shifting towards a model of mGluR5 dysregulation in schizophrenia: Consequences for future schizophrenia treatment. Neuropharmacology. 115, pp. 73 - 91. https://doi.org/10.1016/j.neuropharm.2015.08.003
AuthorsMatosin, Natalie, Fernandez-Enright, Francesca, Lum, Jeremy S. and Newell, Kelly A.
Abstract

Metabotropic glutamate receptor subtype 5 (mGluR5), encoded by the GRM5 gene, represents a compelling novel drug target for the treatment of schizophrenia. mGluR5 is a postsynaptic G-protein coupled glutamate receptor strongly linked with several critical cellular processes that are reported to be disrupted in schizophrenia. Accordingly, mGluR5 positive allosteric modulators show encouraging therapeutic potential in preclinical schizophrenia models, particularly for the treatment of cognitive dysfunctions against which currently available therapeutics are largely ineffective. More work is required to support the progression of mGluR5-targeting drugs into the clinic for schizophrenia treatment, although some obstacles may be overcome by comprehensively understanding how mGluR5 itself is involved in the neurobiology of the disorder. Several processes that are necessary for the regulation of mGluR5 activity have been identified, but not examined, in the context of schizophrenia. These processes include protein–protein interactions, dimerisation, subcellular trafficking, the impact of genetic variability or mutations on protein function, as well as epigenetic, post-transcriptional and post-translational processes. It is essential to understand these aspects of mGluR5 to determine whether they are affected in schizophrenia pathology, and to assess the consequences of mGluR5 dysfunction for the future use of mGluR5-based drugs. Here, we summarise the known processes that regulate mGluR5 and those that have already been studied in schizophrenia, and discuss the consequences of this dysregulation for current mGluR5 pharmacological strategies.

Keywordsmetabotropic glutamate receptor 5; mGluR5; protein regulation; glutamate; schizophrenia; novel therapy
Year2017
JournalNeuropharmacology
Journal citation115, pp. 73 - 91
PublisherPergamon
ISSN0028-3908
Digital Object Identifier (DOI)https://doi.org/10.1016/j.neuropharm.2015.08.003
Scopus EID2-s2.0-84950122652
Page range73 - 91
Research GroupSchool of Behavioural and Health Sciences
Publisher's version
File Access Level
Controlled
Place of publicationUnited Kingdom
Permalink -

https://acuresearchbank.acu.edu.au/item/8v079/shifting-towards-a-model-of-mglur5-dysregulation-in-schizophrenia-consequences-for-future-schizophrenia-treatment

Restricted files

Publisher's version

  • 56
    total views
  • 0
    total downloads
  • 2
    views this month
  • 0
    downloads this month
These values are for the period from 19th October 2020, when this repository was created.

Export as

Related outputs

Molecular evidence of synaptic pathology in the CA1 region in schizophrenia
Matosin, Natalie, Fernandez-Enright, Francesca, Lum, Jeremy S., Engel, Martin, Andrews, Jessica L., Gassen, Nils C., Wagner, Klaus V., Schmidt, Mathias V. and Newell, Kelly A.. (2016). Molecular evidence of synaptic pathology in the CA1 region in schizophrenia. Schizophrenia. 2(16022), pp. 1 - 8. https://doi.org/10.1038/npjschz.2016.22
NMDA receptor antagonism by phencyclidine reduces NWASP and WAVE1 protein expression and reduces levels of myelination markers in the prefrontal cortex of rats
Andrews, Jessica L., Newell, Kelly A., Matosin, Natalie, Huang, Xu-Feng and Fernandez-Enright, Francesca Elizabeth. (2015). NMDA receptor antagonism by phencyclidine reduces NWASP and WAVE1 protein expression and reduces levels of myelination markers in the prefrontal cortex of rats. Journal of Pharmaceutics and Pharmacology. 3(1), pp. 1 - 8.
Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: Towards a model of mGluR5 dysregulation
Matosin, Natalie, Fernandez-Enright, Francesca Elizabeth, Fung, Samantha Jane, Lum, Jeremy Stephen, Engel, Martin, Andrews, Jessica Lee, Huang, Xu-Feng, Weickert, Cynthia Shannon and Newell, Kelly Anne. (2015). Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: Towards a model of mGluR5 dysregulation. Acta Neuropathologica. 130(1), pp. 119 - 129. https://doi.org/10.1007/s00401-015-1411-6
Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats
Andrews, Jessica L., Newell, Kelly A., Matosin, Natalie, Huang, Xu-Feng and Fernandez-Enright, Francesca Elizabeth. (2015). Alterations of p75 neurotrophin receptor and Myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats. Progress in Neuropsychopharmacology and Biological Psychiatry. 56(63), pp. 91 - 97. https://doi.org/10.1016/j.pnpbp.2015.06.003
Genetic variants in Nogo receptor signaling pathways may be associated with early life adversity in schizophrenia susceptibility
Andrews, Jessica L. and Fernandez-Enright, Francesca Elizabeth. (2015). Genetic variants in Nogo receptor signaling pathways may be associated with early life adversity in schizophrenia susceptibility. Biochimica et Biophysica Acta Clinical. 3, pp. 36 - 43. https://doi.org/10.1016/j.bbacli.2014.11.008
Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia
Matosin, Natalie, Fernandez-Enright, Francesca Elizabeth, Lum, Jeremy S., Andrews, Jessica L., Engel, Martin, Huang, Xu-Feng and Newell, Kelly A.. (2015). Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia. Schizophrenia Research. 166(2017-03-01), pp. 212 - 218. https://doi.org/10.1016/j.schres.2015.05.001
Investigation of genetic variants in ubiquitin enzyme genes involved in the modulation of neurodevelopmental processes: A role in schizophrenia susceptibility?
Andrews, Jessica L. and Fernandez-Enright, Francesca. (2014). Investigation of genetic variants in ubiquitin enzyme genes involved in the modulation of neurodevelopmental processes: A role in schizophrenia susceptibility? Genetics Research. 96(e15), pp. 1 - 9. https://doi.org/10.1017/S0016672314000184
Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: Implications for novel mGluR-based therapeutics
Matosin, Natalie, Fernandez-Enright, Francesca, Frank, Elisabeth, Deng, Chao, Wong, Jenny, Huang, Xu-Feng and Newell, Kelly A.. (2014). Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and nonpsychotic depression, bipolar disorder and schizophrenia: Implications for novel mGluR-based therapeutics. Journal of Psychiatry and Neuroscience. 39(6), pp. 407 - 416. https://doi.org/10.1503/jpn.130242
Novel implications of Lingo-1 and its signaling partners in schizophrenia
Fernandez-Enright, F., Andrews, J. L., Newell, K. A., Pantelis, C. and Huang, X.-F.. (2014). Novel implications of Lingo-1 and its signaling partners in schizophrenia. Translational Psychiatry. 4, pp. 1 - 8. https://doi.org/10.1038/tp.2013.121
In vivo pharmacological evaluations of novel olanzapine analogues in rats: A potential new avenue for the treatment of schizophrenia
Jafari, Somayeh, Huang, Xu-Feng, Andrews, Jessica L. and Fernandez-Enright, Francesca. (2013). In vivo pharmacological evaluations of novel olanzapine analogues in rats: A potential new avenue for the treatment of schizophrenia. PLoS ONE. 8(12), pp. 1 - 10. https://doi.org/10.1371/journal.pone.0080979
Novel olanzapine analogues presenting a reduced H 1 receptor affinity and retained 5HT 2A/D 2 binding affinity ratio
Jafari, Somayeh, Bouillon, Marc E., Huang, Xu-Feng, Pyne, Stephen G. and Fernandez-Enright, Francesca. (2012). Novel olanzapine analogues presenting a reduced H 1 receptor affinity and retained 5HT 2A/D 2 binding affinity ratio. BMC Pharmacology. 12(1), pp. 1 - 8. https://doi.org/10.1186/1471-2210-12-8
Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects
Jafari, Somayeh, Fernandez-Enright, Francesca and Huang, Xu-Feng. (2012). Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects. Journal of Neurochemistry. 120(3), pp. 371 - 384. https://doi.org/10.1111/j.1471-4159.2011.07590.x